Hovione Technology collaborates with Bilim on asthma treatment product

Bilim Pharmaceuticals, H&T Presspart and Hovione Technology have announced a collaboration supporting Bilim’s launch of its Ventorfor Combi Fix into the Turkish market

The product is a formulation of Budesonide Formoterol for asthma and COPD management, delivered by the Hovione Technology’s PowdAir Plus dry powder inhaler (DPI). The DPI is manufactured and commercialized exclusively by H&T Presspart under patent license.

The companies’ individual expertise in each of their fields has allowed us to develop a strong partnership in the design, development and manufacture of PowdAir Plus.

“It’s a great pleasure for us to launch our new product Ventofor Combi Fix, collaborating closely with esteemed companies H&T Presspart and Hovione Technology. Ventofor Combi Fix is and will continue to be an important part of our portfolio for the asthma and COPD treatment area.

Okan Oncel, Bilim’s General Manager said: "We are confident that Ventofor Combi Fix will be a remarkable product in its market”.

Christian Kraetzig, H&T Presspart’s President said: “We are very happy to see that Bilim has selected the PowdAir Plus DPI for their launch of Ventofor Combi Fix. This milestone was reached thanks to the strong collaboration of Bilim with Hovione Technology and H&T Presspart.

”The companies’ individual expertise in each of their fields has allowed us to develop a strong partnership in the design, development and manufacture of PowdAir Plus. We look forward to seeing Bilim launch the product to the market and will continue to strongly support them with their inhalation strategy”.

Peter Villax, Hovione Technology’s CEO said: “We are delighted to have started an inhalation collaboration with Bilim, one of Turkey’s largest pharmaceutical companies, and that they selected our PowdAir Plus DPI to bring Ventofor Combi Fix to patients’ hands. We are also happy to continue our partnership with H&T Presspart, a master of large-scale industrialization and distribution, to turn our patented inhaler technology into a commercial ready product that is now globally available to pharmaceutical companies”.

Companies